Medically reviewed by Drugs.com. Last updated on Mar 21, 2023.
Applies to the following strengths: 75 mg
Usual Adult Dose for:
Additional dosage information:
Usual Adult Dose for Migraine
For Acute Treatment of Migraine: 75 mg orally as needed
Maximum dose: 75 mg in a 24-hour period
- The safety of using more than 18 doses in a 30-day period is unknown.
Use: For the acute treatment of migraine with or without aura.
Usual Adult Dose for Migraine Prophylaxis
75 mg orally every other day
Use: For the preventative treatment of episodic migraine.
Renal Dose Adjustments
Mild to Severe Renal Impairment (CrCl 15 mL/min or greater): No adjustment recommended
ESRD (CrCl less than 15 mL/min): Avoid use
Liver Dose Adjustments
Mild to Moderate Hepatic Impairment (Child-Pugh A or B): No adjustment recommended
Severe Hepatic Impairment (Child-Pugh C): Avoid use
Concomitant Use with CYP450 3A4 Inhibitors:
- Strong CYP450 3A4 inhibitors: Avoid concomitant administration
- Moderate CYP450 3A4 inhibitors: Avoid a second dose of rimegepant within 48 hours
Concomitant Use with CYP450 3A4 Inducers:
- Strong or moderate CYP450 3A4 inducers: Avoid concomitant administration as this may lead to loss of efficacy of rimegepant
Concomitant Use with P-gp or BCRP:
- Avoid concomitant administration with P-gp or BCRP inhibitors
- Hypersensitivity to active substance or any product excipients; delayed serious hypersensitivity has occurred
Safety and efficacy have not been established in patients younger than 18 years.
Consult WARNINGS section for additional precautions.
Data not available
- Place on tongue (or under tongue) and allow to disintegrate in saliva and swallow; additional liquid is not necessary
- Do not take more than 1 dose in 24-hours
- Use dry hands when opening the blister pack
- Peel back the foil and gently remove the tablet; do not push tablet through foil
- Place tablet on tongue or under tongue as soon as the blister is opened; do not store tablet outside the blister pack for future use
- Patients should be instructed to read the US FDA-approved patient labeling (Patient Information).
- Patients should be instructed to contact their healthcare provider if they experience signs or symptoms of an allergic reaction.
- Patients should be instructed to speak with healthcare provider about all other medicines they are taking including over the counter medications and herbal supplements.
- Patients should be advised to speak with their healthcare provider if they become pregnant or plan to become pregnant, are breastfeeding or plan to breastfeed during therapy.
Frequently asked questions
- What are the new drugs for the treatment of migraines?
- How do Ubrelvy, Qulipta and Nurtec compare for migraines?
- How fast and effective is Nurtec ODT for migraines?
More about rimegepant
- Check interactions
- Compare alternatives
- Reviews (263)
- Side effects
- During pregnancy
- Drug class: CGRP inhibitors
- En español
Related treatment guides
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.